Trimethoprim Sulfamethoxazole (TMP/SMX)

Phase 2Small molecule

Trimethoprim Sulfamethoxazole (TMP/SMX) is one of 29 small molecule programs targeting Growth. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

GrowthPhase 2

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Aricept

Eisai

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Lenvima

Eisai

Preclinical

1 5

Herceptin

OOrganon and Co

Preclinical

4 6

Somavaratan

Glucophage

2 8

EGRIFTA WR

TTheratechnologies

Preclinical

2 9

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

1 10

Trental

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Resistance1 trial

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT03489629·37 enrolled

Invasive Fungal Disease1 trial

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Active, not recruiting·MMundipharma Research Limited·Phase 3·NCT04368559·602 enrolled

Growth1 trial

Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children

Not yet recruiting·UUniversity of Virginia·Phase 2·NCT07451171·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Trimethoprim Sulfamethoxazole (TMP/SMX). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trimethoprim Sulfamethoxazole (TMP/SMX) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trimethoprim Sulfamethoxazole (TMP/SMX). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Virginia

Trimethoprim Sulfamethoxazole (TMP/SMX)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Resistance1 trial

Invasive Fungal Disease1 trial

Growth1 trial

References

Drug Info

Quick Facts

Related News